Charles Schwab Investment Management Inc Oncocyte Corp Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $84,195 - $149,790	-97,902 Reduced 61.12%	62,284 $57,000
Q3 2021 Nov 16, 2021	SELL	$3.53 - $5.89 $72,820 - $121,504	-20,629 Reduced 11.41%	160,186 $571,000
Q2 2021 Aug 16, 2021	SELL	$3.77 - $6.0 $6,518 - $10,374	-1,729 Reduced 0.95%	180,815 $1.04 Million
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $51,772 - $140,803	21,662 Added 13.46%	182,544 $948,000
Q4 2020 Feb 16, 2021	BUY	$1.38 - $2.63 $29,261 - $55,766	21,204 Added 15.18%	160,882 $385,000
Q3 2020 Nov 13, 2020	BUY	$1.2 - $1.89 $44,480 - $70,056	37,067 Added 36.12%	139,678 $195,000
Q2 2020 Aug 14, 2020	BUY	$1.91 - $3.45 $92,709 - $167,459	48,539 Added 89.77%	102,611 $196,000
Q3 2019 Nov 08, 2019	SELL	$1.59 - $2.51 $6,146 - $9,703	-3,866 Reduced 6.67%	54,072 $114,000
Q2 2019 Aug 09, 2019	BUY	$2.49 - $5.45 $111,268 - $243,538	44,686 Added 337.2%	57,938 $145,000
Q1 2019 May 14, 2019	BUY	$1.47 - $5.91 $19,480 - $78,319	13,252 New	13,252 $53,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $266M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.